Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial (RESET)
Not Applicable
- Conditions
- coronary artery disease
- Registration Number
- JPRN-UMIN000002634
- Lead Sponsor
- RESET trial
- Brief Summary
From February and July 2010, 3197 patients were randomly assigned to receive either EES (1597 patients) or SES (1600 patients). At 1 year, the primary efficacy end point of target-lesion revascularization occurred in 65 patients (4.3%) in the EES group and in 76 patients (5.0%) in the SES group, demonstrating noninferiority of EES to SES (Pnoninferiority<0.0001, and Psuperiority<0.34). Cumulative incidence of definite stent thrombosis was low and similar between the 2 groups (0.32% versus 0.38%, P<0.77).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 3197
Inclusion Criteria
Not provided
Exclusion Criteria
The patients who refuse to participate in this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Any TLR at 1 year Death / MI at 3 years
- Secondary Outcome Measures
Name Time Method Death / MI at 1 year and 2 years Success rate for stent deployment